It depends on the standard you follow. As of September 2026, Azenta, Inc. (AZTA) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 30.8% / 30% · Interest income / Revenue 2.71% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.4% / 33% · Receivables / Mkt Cap (36m) 8.80% / 49% · Interest income / Revenue 2.71% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.4% / 33.33% · Receivables / Mkt Cap (24m) 8.80% / 33.33% · Interest income / Revenue 2.71% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.72% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 19.2% / 33.33% · Receivables / Avg Assets (4Q) 7.99% / 33.33% · Interest income / Revenue 2.71% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 19.5% / 33.33% · (Cash+Recv) / Total Assets 27.9% / 33.33% · Interest income / Revenue 2.71% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Azenta, Inc. (AZTA) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
No. Azenta, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 2.71% of each dividend: Azenta, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Azenta, Inc. (NASDAQ: AZTA) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
Azenta, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $45.81, Azenta, Inc. trades at 3.2x sales and 1.4x book value. Over the last twelve months it generated about $618M of revenue and a net loss of $158M. It runs a gross margin of 44.2%, an operating margin of -27.7% and a net margin of -26.9%. It shows return on equity of -10.8%, return on invested capital of -11.7% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 2.68. Over the past 52 weeks the share price ranged from $15.93 to $50.06, with a beta of 1.47.
Azenta, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 7 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.